IP Library Granted Patent US 8,188,051
Granted Patent B2
US 8,188,051 · App. 12/336,409 · Granted May 29, 2012

Metadherin polypeptides, encoding nucleic acids and methods of use

Assignee: The Burnham Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,188,051
App. No.
12/336,409
Granted
May 29, 2012
Kind
B2
Abstract

Metadherin, a protein that controls metastasis, and variants of metadherin are described. DNA sequences encoding the same and methods of production are described. Therapies involving the application of metadherin, binding agents that bind to metadherin, such as antibodies, and expression modulating agents, such as siRNA, are described. The use of metadherin or metadherin variants for delivering desired substances to particular lung tissue is described. A method of diagnosing metastatic cells based on the presence of metadherin is described.

Claims (20)

1. A method of delivering an agent to the lung vasculature of a patient, comprising:

linking an agent to a metadherin protein to create a metadherin targeted agent, wherein said metadherin protein has an amino acid sequence that is at least 95% identical to the sequence shown in SEQ ID NO: 17, and wherein the agent is a therapeutic agent, a diagnostic agent, or a detectable agent; and

administering said metadherin targeted agent to a patient, thereby delivering an agent to a lung vasculature of the patient.

2. The method of claim 1 wherein said metadherin consists of the amino acid sequence that is at least 95% identical to the sequence shown in SEQ ID NO: 17.

3. The method of claim 1 , wherein said metadherin protein has an amino acid sequence that is identical to the amino acid sequence shown in SEQ ID NO: 17.

4. The method of claim 1 , wherein administering said metadherin targeted agent comprises intravenous administration of said targeted composition.

5. The method of claim 1 , wherein said metadherin protein consists of an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO: 17.

6. The method of claim 1 , wherein metadherin comprises the amino acid sequence of SEQ ID NO: 13.

7. A method of delivering an agent to the lung vasculature of a patient, said method comprising administering an agent linked to a metadherin protein to a patient, wherein said metadherin has an amino acid sequence that is at least 95% identical to the sequence shown in SEQ ID NO: 17, and wherein the agent is a therapeutic agent, a diagnostic agent, or a detectable agent, thereby delivering the agent to a lung vasculature of the patient.

8. The method of claim 7 , wherein the metadherin protein comprises the amino acid sequence of SEQ ID NO: 13.

9. The method of claim 7 , wherein the metadherin protein comprises the amino acid sequence of SEQ ID NO: 17.

10. The method of claim 7 , wherein said metadherin protein consists of an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO: 17.

11. The method of claim 7 , wherein said metadherin protein has an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO: 17.

12. The method of claim 7 , wherein the agent is a therapeutic agent.

13. The method of claim 7 , wherein the agent is a cancer chemotherapeutic agent.

14. The method of claim 7 , wherein the agent is a cancer chemotherapeutic agent for treatment of breast cancer.

15. The method of claim 7 , wherein the agent is a diagnostic agent.

16. The method of claim 7 , wherein the agent is a detectable agent.

17. A method of delivering an agent to the lung vasculature of a patient, said method comprising administering an agent linked to a metadherin protein to a patient, wherein said metadherin protein has an amino acid sequence that has the sequence shown in SEQ ID NO: 17, and wherein the agent is a therapeutic agent, a diagnostic agent, or a detectable agent, thereby delivering the agent to a lung vasculature of the patient.

18. A method of delivering an agent to the lung vasculature of a patient, said method comprising administering an agent linked to a metadherin protein to a patient, wherein said metadherin protein has an amino acid sequence that has the sequence shown in SEQ ID NO: 3, and wherein the agent is a therapeutic agent, a diagnostic agent, or a detectable agent, thereby delivering the agent to a lung vasculature of the patient.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 28, 2022
From: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR; MRDC
Reel/Frame 060920/0175 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2012
From: RUOSLAHTI, ERKKI; BROWN, DARREN M.
To: BURNHAM INSTITUTE, THE
Reel/Frame 028133/0991 →
Continuity (3)
Division 10986466 · Nov 10, 2004
Provisional Application 60519675 · Nov 13, 2003
Related Publication 20090221718A1 · Sep 3, 2009